{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:18:31Z","timestamp":1790518711847,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000104","name":"NASA","doi-asserted-by":"publisher","award":["NNX10AK63H"],"award-info":[{"award-number":["NNX10AK63H"]}],"id":[{"id":"10.13039\/100000104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016482","name":"Drake University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016482","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.antiviral.2018.08.015","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T19:33:53Z","timestamp":1535225633000},"page":"255-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus"],"prefix":"10.1016","volume":"158","author":[{"given":"M. Shea","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie C.","family":"Markovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4734-4575","authenticated-orcid":false,"given":"Dean","family":"Selleseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7583-0805","authenticated-orcid":false,"given":"Alexa V.","family":"DeVita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phiroze","family":"Sethna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.08.015_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei","year":"2009","journal-title":"Infect. Disord. - Drug Targets"},{"key":"10.1016\/j.antiviral.2018.08.015_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.08.015_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM199904223401608","article-title":"Antiviral drugs","volume":"340","author":"Balfour","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.08.015_bib4","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.08.015_bib6","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib7","first-page":"63","article-title":"Synergy of trimethoprim-sulfamethoxazole","volume":"112","author":"Bushby","year":"1975","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.antiviral.2018.08.015_bib8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/JCM.39.4.1334-1338.2001","article-title":"Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma","volume":"39","author":"Caliendo","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib9","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1128\/AAC.00449-16","article-title":"Potency and stereoselectivity of cyclopropavir triphosphate action on human cytomegalovirus DNA polymerase","volume":"60","author":"Chen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib10","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1086\/314487","article-title":"In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome","volume":"178","author":"Cherrington","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.08.015_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.08.015_bib12","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM199609053351007","volume":"335","author":"Crumpacker","year":"1996","journal-title":"Ganciclovir. N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.08.015_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"De Clercq","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.08.015_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1086\/650463","article-title":"Cytomegalovirus resistance testing: pitfalls and problems for the clinician","volume":"50","author":"Drew","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.08.015_bib18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/infdis\/163.4.716","article-title":"Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection","volume":"163","author":"Drew","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.08.015_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.08.015_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","article-title":"Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus","volume":"56","author":"Evers","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.08.015_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/17512433.2015.1086266","article-title":"Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?","volume":"8","author":"Fabrizi","year":"2015","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1586\/14787210.2014.948847","article-title":"Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses","volume":"12","author":"Florescu","year":"2014","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"10.1016\/j.antiviral.2018.08.015_bib23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2010.09.005","article-title":"Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase","volume":"81","author":"Gentry","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib24","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1128\/AAC.00468-10","article-title":"Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir","volume":"54","author":"Gentry","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib25","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0166-3542(94)90251-8","article-title":"The disposition in rats and monkeys of 2-Bromo-5,6-Dichloro-1-(\u03b2-D-Ribofuranosyl)-Benzimidazole (BDCRB) and its 2,5,6-trichloro congener (TCRB)","volume":"23","author":"Good","year":"1994","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.08.015_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2008.12.015","article-title":"GSK983: a novel compound with broad-spectrum antiviral activity","volume":"82","author":"Harvey","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.08.015_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040334","article-title":"Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic","volume":"4","author":"Heiden","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2018.08.015_bib29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/514249","article-title":"Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV retinitis and viral resistance study group","volume":"177","author":"Jabs","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.08.015_bib30","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1128\/AAC.00571-11","article-title":"Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase","volume":"55","author":"James","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib31","first-page":"927","article-title":"Antiretroviral therapy for prevention of human immunodeficiency virus infection","volume":"100","author":"Kalapila","year":"2016","journal-title":"Med. Clin."},{"key":"10.1016\/j.antiviral.2018.08.015_bib32","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.1128\/JVI.77.14.7720-7727.2003","article-title":"The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase","volume":"77","author":"Krosky","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib33","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/JVI.72.6.4721-4728.1998","article-title":"Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56","volume":"72","author":"Krosky","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0163-7258(03)00034-2","article-title":"The human cytomegalovirus","volume":"98","author":"Landolfo","year":"2003","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.antiviral.2018.08.015_bib35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.antiviral.2018.08.015_bib37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.08.015_bib38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.08.015_bib39","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.3748\/wjg.v20.i31.10658","article-title":"Cytomegalovirus infection in liver transplant recipients: updates on clinical management","volume":"20","author":"Marcelin","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib40","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib41","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.08.015_bib42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.08.015_bib43","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.antiviral.2018.08.015_bib44","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.bbmt.2016.01.009","article-title":"Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo-controlled, parallel-group Phase 3 trial","volume":"22","author":"Marty","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2018.08.015_bib45","first-page":"269","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.antiviral.2018.08.015_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/1319-2442.106250","article-title":"Cytomegalovirus disease in a renal transplant recipient: the importance of pre-transplant screening of the donor and recipient","volume":"24","author":"Mitwalli","year":"2013","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"10.1016\/j.antiviral.2018.08.015_bib47","first-page":"24","article-title":"Comparison of HCMV loads using in-house quantitative CMV PCR, artus CMV PCR, and COBAS amplicor CMV monitor test","volume":"4","author":"Okada","year":"2010","journal-title":"Silpakorn Univ. Sci. Technol. J."},{"key":"10.1016\/j.antiviral.2018.08.015_bib48","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.08.015_bib51","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/nar\/30.7.1695","article-title":"The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with torodial structure","volume":"30","author":"Scheffczik","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.08.015_bib52","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1128\/AAC.47.4.1468-1471.2003","article-title":"Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication","volume":"47","author":"Selleseth","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejphar.2004.07.114","article-title":"Magnitude and time course of platelet inhibition with Aggrenox\u00ae and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial","volume":"499","author":"Serebruany","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib54","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1099\/vir.0.81891-0","article-title":"Latency and reactivation of human cytomegalovirus","volume":"87","author":"Sinclair","year":"2006","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.08.015_bib55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0022-3565(24)29450-7","article-title":"Drug synergism: its detection and applications","volume":"298","author":"Tallarida","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.antiviral.2018.08.015_bib56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.antiviral.2018.08.015_bib57","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/jm00020a025","article-title":"Design, synthesis, and antiviral activity of certain 2,5,6-Trihalo-1-(\u03b2-D-ribofuranosyl)benzimidazoles","volume":"38","author":"Townsend","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.08.015_bib58","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib59","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2018.08.015_bib60","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation","volume":"41","author":"Xiong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.08.015_bib61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/jm030316s","article-title":"Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides","volume":"47","author":"Zhou","year":"2004","journal-title":"J. Med. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218303176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:30:24Z","timestamp":1759062624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218303176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":61,"alternative-id":["S0166354218303176"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.08.015","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}